Risperidone-induced neuroleptic malignant syndrome: a case report and review.
OBJECTIVE
1. To report the case of a 53-year-old patient who developed neuroleptic malignant syndrome (NMS) - a rare but potentially life-threatening complication of neuroleptic therapy - 4 days after treatment with risperidone was initiated. 2. To review previously reported cases of NMS associated with risperidone.


METHODS
A computerized search of several databases, including MEDLINE, was conducted to find all previously reported cases of NMS with risperidone.


RESULTS
Five reported cases of risperidone-induced NMS were found in the literature. All cases including the one reported here displayed typical clinical features of NMS and all 6 patients had a prior history of extrapyramidal side effects and/or NMS. Age and duration of exposure to risperidone did not seem to be of significance.


CONCLUSIONS
These cases illustrate that clinicians should be on the lookout for risperidone-induced NMS.
Meterissian
G B
GB
Department of Psychiatry, McGill University, St. Mary's Hospital Center, Montreal, Quebec.
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018967:Risperidone